11:20 AM EST - Antibe Therapeutics Inc. : Provided a corporate update. Further to Antibe’s update of February 15, 2023, the Company has now selected a clinical research organization to carry out the pharmacokinetic/pharmacodynamic study for otenaproxesul’s new formulation. The purpose of the PK/PD study is to confirm the optimal dosing regimens for the Phase II bunionectomy trial, slated to initiate in calendar Q4 2023 as previously announced. Antibe Therapeutics Inc.
shares T.ATE are trading down $0.02 at $0.54.
